

Seoul International Digestive Disease Symposium 2025

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 19-20, 2025 | Swiss Grand Hotel Seoul, Korea



SIDDS 2025

Frontiers in Digestive Research and Practice

Name	Prof Alessandro Armuzzi, MD PhD
Affiliation	Lead IBD Center, Humanitas Research Hospital-Humanitas University, Milan
Country	Italy
Major Field	Inflammatory Bowel Disease

Educational Background

1993: Degree cum Laude in Medicine and Surgery, University of Bologna, Italy
1998: Consultant in Internal Medicine, Catholic University, Rome, Italy
2000: PhD in Physiology, Tor Vergata University, Rome, Italy
2000-2002: Research fellow, Gastroenterology Unit and Gibson Laboratories Oxford University, NHS Trust Oxford Radcliffe Hospitals, UK

Professional Experience

2000-2002: Honorary fellow Department of Gastroenterology John Radcliffe Hospital, Oxford, UK
2003-2012: Consultant in Internal Medicine and Gastroenterology, Policlinico A. Gemelli, Rome, Italy
2013-2017: Clinical Researcher of Internal Medicine and Gastroenterology, Lead IBD Unit, Policlinico A. Gemelli, Rome, Italy
2017-2021: Associate Professor of Gastroenterology, Lead IBD Unit at Fondazione Policlinico Universitario A. Gemelli IRCCS – Catholic University, Rome, Italy
2022-current: Full Professor of Gastroenterology, Lead IBD Center at IRCCS Humanitas Research Hospital, Rozzano, Milan – Department of Biomedical Sciences Humanitas University, Pieve Emanuele, Milan, Italy
2023-current: 2023-current: Director of Gastroenterology Residency Program at Humanitas University, Pieve Emanuele, Milan, Italy

Main Recent Scientific Publications

1. Maselli R, de Sire R, Barbaro F, Cecinato P, Andrisani G, Rosa-Rizzotto E, Sferrazza S, Fiori G, Azzolini F, Pugliese F, Facciorusso A, Spadaccini M, Capogreco A, Massimi D, Alfarone L, Chiappetta MF, Gubbiotti A, Menini M, Khalaf K, Sassatelli R, Di Matteo FM, Spada C, Hassan C, Repici A, Armuzzi A. Outcomes of endoscopic submucosal dissection for high-risk colorectal colitis-associated neoplasia in inflammatory bowel disease. *Endoscopy*. 2025 Feb 24. doi: 10.1055/a-2524-3553.
2. Gabbiadini R, Spaggiari P, Figlioli G, Iuzzolino M, Dal Buono A, Bezzio C, Repici A, Spinelli A, Piovani D, Bonovas S, Armuzzi A. Impact of histologic disease activity on long-term outcomes in patients with ileal pouch-anal anastomosis for ulcerative colitis. *.Dig Liver Dis*. 2025 Jan 29:S1590-8658(25)00180-X. doi: 10.1016/j.dld.2025.01.180.
3. Armuzzi A, Vermeire S, Chaparro M, Biedermann P, Brown R, McStravick M, Meyer M, Schreiber S. Effectiveness and Treatment Persistence of Vedolizumab Compared to Anti-Tumour Necrosis Factor- α in Patients With Crohn's Disease: A Systematic Literature Review and Meta-Analysis. *United European Gastroenterol J*. 2024 Dec 21. doi: 10.1002/ueg2.12705.



Main Recent Scientific Publications

- Dubinsky MC, Wu J, McDonnell A, Lazin K, Goetsch M, Branquinho D, Modesto I, Armuzzi A. Low Incidence of Macular Edema and Other Ocular Events in the Etrasimod Development Program. *J Crohns Colitis*. 2024 Nov 22;jjae173. doi: 10.1093/ecco-jcc/jjae173.
- D'Haens G, Taxonera C, Lopez-Sanroman A, Nos P, Danese S, Armuzzi A, Roblin X, Peyrin-Biroulet L, West R, Mares WGN, Duijvestein M, Gecse KB, Feagan BG, Zou G, Hulshoff MS, Mookhoek A, Oldenburg L, Clasquin E, Bouhnik Y, Laharie D. Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial. *Lancet Gastroenterol Hepatol*. 2025;10(1):26-33.
- Cammarota G, Laterza L, Bibbò S, Fusco W, Rozera T, Di Brino E, Porcari S, Scaldaferri F, Ianiro G, Gasbarrini A, Armuzzi A. Green Management of IBD-New Paradigms for an Eco-Friendly Approach. *Aliment Pharmacol Ther*. 2025 Jan;61(1):65-74.
- Parigi TL, Massimino L, Carini A, Gabbiadini R, Bertoli P, Allocca M, Bezzio C, Dal Buono A, D'Amico F, Furfaro F, Loy L, Zilli A, Ungaro F, Jairath V, Peyrin-Biroulet L, Armuzzi A, Danese S. Prevalence, characteristics, management, and outcomes of difficult-to-treat inflammatory bowel disease. *J Crohns Colitis*. 2024 Sep 12;jjae145. doi: 10.1093/ecco-jcc/jjae145.
- Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr. Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials. *JAMA*. 2024 Sep 17;332(11):881-897.
- Louis E, Litkiewicz M, Agboton C, Armuzzi A. Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence. *United European Gastroenterol J*. 2024 Jun;12(5):574-584.
- Armuzzi A, Cross RK, Lichtenstein GR, Hou J, Deepak P, Regueiro M, Wolf DC, Akukwe L, Ahmad HA, Jain A, Kozinn M, Wu H, Petersen A, Charles L, Long M. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses. *Clin Gastroenterol Hepatol*. 2024 May;22(5):1067-1076.